The use of inhibitors of bruton's tyrosine kinase (BTK)

BNRE20230001BUndetermined Publication Date: 2023-10-31PHARMACYCLICS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BNRE20230001
Authority / Receiving Office
BN · BN
Patent Type
Patents
Current Assignee / Owner
Priority Date
2011-04-05
Filing Date
2011-06-03
Publication Date
2023-10-31
Estimated Expiration
2031-06-03

Smart Images

  • Figure IMAGE_001
    Figure IMAGE_001
  • Figure IMAGE_002
    Figure IMAGE_002
  • Figure IMAGE_003
    Figure IMAGE_003
Patent Text Reader

Abstract

Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Need to check novelty before this filing date? Find Prior Art